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A B S T R A C T
Background: Given the continuous knowledge progression and the growing number of available
antiepileptic drugs (AEDs), making appropriate treatment choices for patients with epilepsy is
increasingly difﬁcult. While published guidelines help for separate clinical aspects, patients with a
combination of speciﬁc characteristics may escape proper guidance. This study aimed to determine the
appropriateness of AEDs for particular clinical variables and to offer treatment recommendations for
adult patients with epilepsy in a user-friendly format for practicing neurologists.
Methods: Using the RAND/UCLA Appropriateness Method, the appropriateness of AEDs as initial/second
mono-therapy and combination therapy was assessed in relation to selected clinical variables by a
Belgian panel of 13 experts in epilepsy. Panel recommendations for particular patient proﬁles were
determined by the outcome of these separate ratings.
Results: The appropriateness outcome of individual AEDs was not substantially different between ﬁrst
and second mono-therapy; valproate was considered appropriate for all types of generalised and partial
seizures. The outcome for combination therapy was highly dependent on the type of AED and seizures.
With respect to co-morbidities and co-treatments, levetiracetam and pregabalin proved to have the least
contra-indications. For the elderly and with respect to factors related to the female reproductive system
the appropriateness of AEDs showed a more diffuse pattern. Although caution was deemed necessary for
some combinations, the AEDs were never considered inappropriate regarding their drug interaction
proﬁle.
Conclusions: The Epi-Scope1 tool that displays appropriateness recommendations for highly speciﬁc,
possibly complex cases, supports optimal treatment choices for adult patients with epilepsy in daily
practice.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +32 2 5553429; fax: +32 2 5553942.
E-mail address: blegros@ulb.ac.be (B. Legros).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.09.0071. Introduction
The epilepsies are a widespread and heterogeneous group of
chronic neurological diseases for which pharmacotherapy is still
the mainstay treatment.1 Considerable efforts have been madevier Ltd. All rights reserved.
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and formulations.2,3 Consequently, the pharmaceutical arsenal of
AEDs has enlarged considerably and has become increasingly
complex with respect to mechanism of action and safety/
tolerability. In daily clinical practice, many different treatment
strategies are used consecutively, often by ‘‘trial and error’’. A less
directive approach could play a role in the relatively large
population of medically refractory patients (about one third of
those with newly diagnosed epilepsy) that still exists.4 In addition,
recent clinical insights have inﬂuenced the deﬁnition of epileptic
syndromes and led to the identiﬁcation of novel therapeutic
indications.5
The continuous evolution in knowledge and drug develop-
ment makes it challenging for the general neurologist to keep
track of the different (contra-)indications of AEDs and their
combinations in relation to particular patient characteristics.
Making appropriate treatment choices in face of an individual
patient with epilepsy may be increasingly difﬁcult, despite the
existence of renowned and high-quality guidelines from leading
neurological associations such as the International League
Against Epilepsy (ILAE) and the American Academy of Neurology
and the American Epilepsy Society (AAN/AES).6,7 Also the
National Institute for Clinical Excellence and the Scottish
Intercollegiate Guidelines Network published a management
guide.8,9 Current therapeutic guidelines, however, present
somewhat conﬂicting recommendations and are very meticu-
lously focussed on the indication itself, leaving other clinical
aspects (apart from advanced age6,7) largely unattended because
of scant evidence. Moreover, they usually do not cover complex
patient proﬁles that present with co-existing morbidities,
concomitant treatments and other parameters that complicate
disease management. It is fairly unlikely that these types of
complex patients will be studied in randomised controlled trials,
leading to evidence-based data. Nevertheless, some kind of
guidelines to help physicians treating these patients would be
welcomed.
It therefore felt desirable as well as useful to develop
recommendations on the appropriate use of AEDs in relation to
relevant clinical aspects in adult patients with epilepsy and[(Fig._1)TD$FIG]
Fig. 1. Conceptual model of the panel study. Treatment recommendations for adult
antiepileptic drugs (AEDs) with respect to particular clinical variables.secondly, to embed these into a user-friendly software program to
allow easy access for neurologists in daily clinical practice.
2. Methods
2.1. Panel process
The appropriateness of AEDs for particular patient proﬁles was
assessed using the RAND/UCLA Appropriateness Method
(RAM).10,11 This modiﬁed Delphi method consists of an iterative
process of individual rating rounds and plenary discussions, and
has been applied in various ﬁelds of medicine.12 The RAM has been
extensively tested for its internal consistency and external
validity.12 The panel process consisted of the following steps.
A panel of 13 Belgian neurologists accepted to participate. The
rationale for this number is a trade-off between permitting
diversity of representation/opinion and involving all in group
discussions. Panel selection was based on expertise in the ﬁeld of
epilepsy and geographical distribution in order to ensure regional
representation across Belgium.
Panellists convened for a ﬁrst panel meeting to discuss the
conceptual framework and starting points of the study. The panel
distinguished between 7 groups of clinical variables that
determine treatment choice in adult (16+) patients with epilepsy
(Fig. 1). These variables were further speciﬁed (e.g. age 16–64 or
65 years, different co-morbidities, different co-treatments, etc.).
Treatment decisions were divided into 3 categories: initial mono-
therapy, secondmono-therapy, and combination of 2 AEDs. It was
decided to consider only AEDs that are commonly available for the
indication of epilepsy in Belgium. The appropriateness of these
medications was then individually rated by the panellists for
every option included (in total 1128 ratings per panel member),
using a 9-point scale (1 = inappropriate, 9 = appropriate). To
facilitate an efﬁcient scoring process, an electronic rating program
was used.
Individual ratingswere aggregated to panel statements for each
of the options, using the mathematical rules that are typically
applied in RAM studies.11 An optionwas considered ‘appropriate’ if
the median panel score was between 7 and 9 without disagree-(16+) patients with epilepsy were formulated based on the appropriateness of
Table 1
Clinical variables and medications included in the ﬁnal ratings.
Clinical variables
Age
16–64 years 65 years
Type of seizures
Initial and second mono-therapy
a. Generalised Tonic–clonic
Absence
Myoclonic
b. Focal Not secondary generalised
Secondary generalised
Combination therapy
a. Generalised
b. Focal
Response to previous treatment (second mono-therapy)
a. Initial medication
b. Reason of treatment failure Insufﬁcient response (despite optimal doses)
Poor tolerance
Co-morbid conditions
Renal insufﬁciency
Kidney stones
Hepatic disease
Porphyria
Auto-immune disease
Mitochondriopathy
Cardiovascular disease
Diabetes mellitus
HIV
Osteoporosis
Obesity
Depression/anxiety
Psychosis
Migraine
Insomnia
Somnolence
Mental retardation/low IQ
Co-treatments
Chronic anticoagulants
Psychopharmaca
Antibiotics
Chemotherapy
Corticosteroids
Diuretics
Radiotherapy
PPI/antacids
Lipid-lowering drugs
Factors related to the female reproductive system
Child bearing factors (pregnancy, child wish, breast feeding)
Use of oral contraception
Interactions
All potential interactions between the AEDs listed below
Medications
Mono-therapies
Carbamazepine
Ethosuximide
Lamotrigine
Levetiracetam
Oxcarbazepine
Phenobarbital
Phenytoin
Topiramate
Valproate
Combination therapies
Baseline Add-ons
Carbamazepine
Lamotrigine
Levetiracetam
Oxcarbazepine
Phenobarbital
Phenytoin
Topiramate
Valproate
Benzodiazepines
Carbamazepine
Ethosuximide
Gabapentin
Lamotrigine
Levetiracetam
Oxcarbazepine
Phenobarbital
Phenytoin
Pregabalin
Primidone
Tiagabine
Topiramate
Valproate
Vigabatrin
B. Legros et al. / Seizure 21 (2012) 32–3934ment between panellists, and ‘inappropriate’ if the median was
between 1 and 3. Agreement corresponds with at least 9 individual
scoreswithin the same category (1–3, 4–6 or 7–9). Disagreement is
deﬁned as the situation in which at least 4 panel members (i.e. one
third of the panel) had scores in each of the sections 1–3 and 7–9.
Options for which disagreement existed or for which the median
score was between 4 and 6 were deemed ‘use with caution’.
The panel then convened to discuss the results, focusing on the
interpretation of deﬁnitions and clinical variables used, and on
potentially redundant or missing conditions and medications. The
discussion led to some adaptations of the ratingmodel (addition of
some conditions and deletion of others, reﬁnement of some
deﬁnitions), after which a second individual rating round was
conducted (1428 ratings per panellist). Based on the second round
ratings, a prototype of the electronic decision support tool was
developed (see next section), which was piloted during education-
al meetings for Belgian general (non-specialised) neurologists, and
chaired by the panel members.
Based on the feedback of these meetings, a third rating round
was conducted, in which some new clinical variables were addedand other options were re-rated. The ﬁnal rating structure,
including 1529 options, is summarised in Table 1.
2.2. Electronic decision tool
The recommendations were embedded in an electronic
decision support tool, structured around the main treatment
decisions: initial mono-therapy, second mono-therapy (after
insufﬁcient response to, or poor tolerability of the initial mono-
therapy), and combination therapy (after unsatisfactory response
to mono-therapy). Appropriateness ratings of the panel for the
separate conditions were combined to overall panel recommen-
dations for any patient proﬁle to be selected, using the following
rules:1. If the treatment is appropriate for all conditions, the outcome is
‘appropriate’2. If any of the panel ratings of the treatment for the separate
conditions is inappropriate, the outcome is ‘inappropriate’3. All other situations result in the outcome ‘use with caution’
[(Fig._2)TD$FIG]
Fig. 2. Appropriateness of antiepileptic drugs as initial mono-therapy in relation to the type of seizures. Red, inappropriate; green, appropriate; yellow, use with caution.
Figures in boxes represent themedian panel scores. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to theweb version of the article.)
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Disagreement amongst the panellists was low and dropped
from 2.6% in the ﬁrst round to 0.5% in the ﬁnal round (all options
together).
3.1. Initial mono-therapy
The panel ratings on the appropriateness of 9 AEDs as initial
mono-therapy show marked patterns in relation to the type of
seizures (Fig. 2). Valproate was the only medication considered
appropriate for all types of seizures. Phenobarbital and phenytoin
were deemed inappropriate for all types of generalised seizures,
and were also less favoured in focal disease.
3.2. Second mono-therapy
Although the panel rated all 9 AEDs also separately as second
mono-therapy by taking into account the initial medication and
type of treatment failure (insufﬁcient response or poor tolerability)
for each of these, the ﬁgures differ only slightly from those of the
initial mono-therapy. In 52 out of the 720 ratings (7.2%) the
outcomes differed from those in Fig. 2, but never with more than 1
appropriateness class, and mostly with less than 1 point difference
on the 9-point scale. The most pronounced differences were found
for phenobarbital (always inappropriate as a second mono-
therapy, regardless of the type of seizures), phenytoin (mostly
inappropriate in focal, not-secondary generalised disease), and
topiramate (appropriate in myoclonic seizures).
3.3. Combination therapy
The rating results for combination therapy are summarised in
Table 2. Although the panel chose to include primidone and
vigabatrin in the ratings, their use as an add-on was consistently
rated inappropriate. Four out of 15 AEDswere deemed appropriate
for generalised seizures, versus 7 for focal disease. These were all
AEDs that could also be used as mono-therapy with the exception
of pregabalin (for focal disease).
3.4. Co-morbidities and co-treatments
The ratings for co-morbidities and co-treatments show diffuse
patterns for the 15 AEDs considered (Table 3). The vast majority of
non-appropriate ratings concerns ‘use with caution’, while around10% relates to ‘inappropriate’ use. Both for co-morbidities and co-
treatments, least (relative) contra-indications were seen for
levetiracetam and pregabalin, while phenobarbital, phenytoin,
and primidone showed the poorest proﬁles in this respect.
3.5. Advanced age and factors related to the female reproductive
system
The panel considered advanced age (65 years) to be a contra-
indication for the use of phenobarbital, phenytoin, and primidone.
Benzodiazepines, carbamazepine, ethosuximide, oxcarbazepine,
tiagabine and vigabatrin were recommended to be ‘used with
caution’ in elderly patients. Concerning child-bearing factors
(breast feeding, pregnancy or planning to become pregnant), all
AEDswarrant at least cautious use,while phenobarbital, phenytoin
and primidonewere deemed ‘inappropriate’. For women using oral
contraceptives, benzodiazepines, gabapentin, levetiracetam, preg-
abalin, tiagabine, valproate and vigabatrin were considered to be
safe options. All other AEDs were advised to be ‘used with caution’,
except for phenobarbital and primidone (both inappropriate).
3.6. Interactions between AEDs
The ratings on interactions between AEDs (Table 4) revealed no
inappropriate combinations, although cautious use was recom-
mended for some. Best results were seen for levetiracetam and
topiramate. For the add-ons, gabapentin and pregabalin showed
the most favourable interaction proﬁles.
3.7. Epi-Scope1
The ﬁnal rating results formed the basis for the development of
an electronic decision support program, called Epi-Scope1. A
patient proﬁle can be chosen by selecting the different clinical
variables (Fig. 3). In total, the tool allows around 45 billion different
combinations of patient proﬁles. The appropriateness of AEDs for a
selected proﬁle is displayed using corresponding colours; green
indicates that the medication is appropriate in the given situation,
yellow means ‘use with caution’, while red corresponds to an
inappropriate choice (Fig. 4). (For interpretation of the references
to colour in this ﬁgure, the reader is referred to the web version of
the article.) By clicking on any of the AED boxes, the reasons behind
the recommendations are explained (Fig. 4). Additional informa-
tion on indications and reimbursement conditions (speciﬁcally for
Belgium) is available via links to governmental sites on pharma-
Table 2
Appropriateness of add-ons to 8 initial (baseline) antiepileptic drugs.a
Add-on Generalised seizures Focal disease
Benzodiazepines Mostly inappropriate, except with
carbamazepine and valproate (caution)
Inappropriate
Carbamazepine Inappropriate with phenobarbital and
phenytoin; others: caution
Appropriate except with
oxcarbazepine (caution)
Ethosuximide Use with caution Inappropriate
Gabapentin Inappropriate Use with caution
Lamotrigine Appropriate Appropriate
Levetiracetam Appropriate Appropriate
Oxcarbazepine Use with caution, except with
phenytoin (inappropriate)
Appropriate, except with
carbamazepine (caution)
Phenobarbital Inappropriate Use with caution
Phenytoin Inappropriate Use with caution
Pregabalin Inappropriate Appropriate
Primidone Inappropriate Inappropriate
Tiagabine Inappropriate Use with caution
Topiramate Appropriate Appropriate
Valproate Appropriate Appropriate
Vigabatrin Inappropriate Inappropriate
a Carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproate.
Table 3
Antiepileptic drugs rated by the panel as ‘use with caution’ or ‘inappropriate’ in light of co-morbidities and co-treatments. Inappropriate medications are marked with an *.
Co-morbidities
Renal insufﬁciency BZD, CBZ, GBP, LEV, OXC, PB, PHT, PGB, PRM, TPM, VGB
Kidney stones TPM*
Hepatic disease BZD, CBZ, ESM, LTG, OXC, PB, PHT, PRM, TGB, TPM, VPA
Porphyria BZD, CBZ, ESM, LTG, OXC, PB*, PHT*, PRM*, TGB, TPM, VPA*, VGB
Auto-immune disease CBZ, ESM, LTG, OXC, PB, PHT, PRM, TGB, VPA
Mitochondriopathy BZD, CBZ, OXC, PB, PHT, PRM, TGB, TPM, VPA*, VGB
Cardiovascular disease CBZ, OXC, PB, PHT, PRM
Diabetes mellitus PHT, VPA
HIV BZD, CBZ, ESM, OXC, PB, PHT, PRM, TPM, VPA
Osteoporosis CBZ, OXC, PB*, PHT*, PRM, TPM, VPA
Obesity GBP, PB, PGB, VPA, VGB
Depression/anxiety ESM, GBP, PB, PRM, TGB, TPM, VGB
Psychosis BZD, ESM, GBP, LTG, LEV, PB, PHT, PRM, TGB, TPM, VGB
Migraine –
Insomnia LTG
Somnolence BZD*, CBZ, ESM, GBP, LEV, OXC, PB*, PHT, PGB, PRM*, TGB, TPM, VPA, VGB
Mental retardation/low IQ BZD, ESM, GBP, LEV, PB, PHT, PGB, PRM*, TGB, TPM, VGB
Co-treatments
Chronic anti-coagulants BZD, CBZ, ESM, OXC, PB*, PHT*, PRM*, VPA
Psychopharmaca BZD, CBZ, OXC, PB, PHT, PRM, TPM, VPA
Antibiotics CBZ, ESM, LTG, OXC, PB, PHT, PRM
Chemotherapy CBZ, ESM, LTG, OXC, PB, PHT, PRM, TPM, VPA
Corticosteroids CBZ, ESM, OXC, PB, PHT, PRM
Diuretics CBZ, OXC, PB, PHT, PRM, TPM
Radiotherapy CBZ*, LTG, PB*, PHT*, PRM*
PPI/antacids CBZ, GBP, OXC, PB, PHT, PRM, TGB
Lipid-lowering drugs CBZ, ESM, OXC, PB, PHT, PRM, TGB, TPM, VGB
BZD, benzodiazepines; CBZ, carbamazepine; ESM, ethosuximide; GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PB, phenobarbital; PHT,
phenytoin; PGB, pregabalin; PRM, primidone; TGB, tiagabine; TPM, topiramate; VGB, vigabatrin; VPA, valproate.
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English via: http://www.e-hims.com/episcope_demo/.
4. Discussion
Using amodiﬁed RAND approach, the study summarised expert
opinion, i.e. clinical evidence combined with personal experience
where the medical literature is insufﬁcient to determine the
appropriateness of different AEDs in relation to particular patient-
speciﬁc clinical conditions. Following logical principles, treatment
recommendations were then formulated based on the combina-
tion of panel outcomes for these separate aspects. When at least
one aspect was deemed not appropriate (uncertain or inappropri-
ate), the ﬁnal outcome for a patient proﬁle with that aspect wasconsidered accordingly. Recommendations were calculated by this
methodology for all patient proﬁles that can be created with the
clinical variables selected in this study. The total number of distinct
cases with epilepsy that the study covers reaches 45 billion.
To provide a clear and concise display of the results, the data
were embedded into an electronic tool, which is a real asset to
further broaden the applicability and usefulness of the study
outcome. In contrast to tables and listings, the tool allows easy
extraction of the panel’s recommendations in a few ‘clicks’. In
addition, when encountering a patient with epilepsy, the Epi-
Scope1 program could be used as ‘professional mirror’ in the
consultation ofﬁce; physicians can compare their own treatment
decisions with that of the panel. The Epi-Scope1 decision support
tool does not replace clinical judgement; it merely indicates
[(Fig._3)TD$FIG]
Fig. 3. User interface of Epi-Scope1. Example of a patient proﬁle.
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individual patient proﬁles. Furthermore, the display of reasons
behind the given recommendation is an additional advantage and
allows using the tool for educational purposes. Besides at the
personal level the tool can be deployed to discuss patient cases
within the framework of continuing medical education.
[(Fig._4)TD$FIG]
Fig. 4. Display of the medication recommendations (right) and considerations beIn some respects, the study recommendations (and Epi-Scope1
program) are relatively similar to the recommendations of the ILAE
and AAN/AES, that have been published some years ago6,7 and
which, inherent to the methodology of study qualiﬁcation, merely
reﬂect evidence-based data. For an adult patient with partial
seizures for instance, the ILAE guidelines considered CBZ and PHThind a selected recommendation for combination therapy as pop-up (left).
Table 4
Potential interactions between antiepileptic drugsa (use with caution). None of the
combinations was rated inappropriate.
Carbamazepine BZD, ESM, LTG, OXC, PB, PHT, PRM, TGB
Lamotrigine CBZ, PB, PHT, PRM
Levetiracetam –
Oxcarbazepine CBZ, ESM, PB, PHT, PRM
Phenobarbital BZD, CBZ, ESM, LTG, OXC, PHT, PRM, TGB, VPA
Phenytoin BZD, CBZ, ESM, LTG, OXC, PB, PRM, VPA
Topiramate VPA
Valproate LTG, PB, PHT, PRM, TPM, VGB
a See Table 3 for explanation of medication abbreviations.
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guidelines give recommendations only for newer AEDs, GBP, LTG,
OXC and TPM received a level A or B for use. In comparison, our
study recommends CBZ, LEV, LTG, OXC, TPM and VPA for a 30-year-
old man with partial seizures and no co-morbidity/co-medication.
These drugs are indicated to be used as mono-therapy in Belgium,
which is not the case for GBP. The panel considered PHT (as well as
PB) as to be ‘used with caution’ due to long-term safety issues. LEV
was included as appropriate based on the more recently published
study of the drug in new-onset partial seizures.17 Similar results
were obtained in previously published expert opinion studies
conducted in the US13,14 and in Belgium,15,16 which recommended
CBZ, OXC, LTG and LEV.14,16 As such, the study outcome is a
combination of existing clinical data (causing similarities with the
current guidelines) and experiences/opinion of experts in the ﬁeld.
One of the major strengths of this study/tool, making it unique
versus guidelines and other expert panel studies is that guidance is
given for composite clinical cases, e.g. with multiple co-morbid-
ities, co-treatments and other patient variables that are important
for treatment choice (e.g. advanced age, breast feeding, etc.). The
vast majority of these special populations are excluded from
participation in clinical studies, which causes evidence-based
medicine and current guidelines to be rather limited in this
respect. Consequently, the recommendations for complex cases in
this study reﬂect rather medicine-based evidence than evidence-
based medicine, and panel recommendations could be considered
a useful complement to existing international guidelines. To
illustrate this with a patient proﬁle that is relatively common in
practice, valproate is considered as an appropriate ﬁrst mono-
therapy in our study for a 32-year-old female patient with
generalised tonic–clonic seizures who takes oral contraception,
similar to established guidelines and other panel studies (level C,
no AED has level A or B).6,7,14,16 When this patient also presents
with kidney stones and obesity and takes PPI/antacids, the tool’s
recommendation for valproate turns into ‘use with caution’ due to
obesity as co-morbidity, leaving levetiracetam as an appropriate
treatment option. Speciﬁc recommendations for such a case cannot
be extracted from existing literature sources.6,7,14,16
One of the limitations of the study – inherent to the
methodology – is that the recommendations reﬂect ‘‘expert
opinion’’, which may change very rapidly. Therefore, the results
of this study could be considered a ‘snapshot’ of the current
situation in Belgium. Given the continuous advances of clinical
science and experiences, periodical updates are warranted to keep
the treatment recommendations up-to-date. Therefore, annual re-
ratings are taking place based upon the publication of novel
relevant data, retrieved from regular literature searches by a
steering committee of 3 panel members. Obviously, new AEDs
need to be included as well (e.g. lacosamide, which has been
available in Belgium since March 2010). Compared to distributing
study results in printed version, using software in an internet
environment allows timely and easy updates once new rating
results become available. A further constraint relates to theincluded co-morbidities and co-treatments.While these constitute
the most frequent/relevant ones for patients with epilepsy, not all
existing could be covered. To ensure a reasonable balance between
rating feasibility and the extent of recommendations, some
categories such as ‘cardiovascular disease’ have been kept fairly
large, covering multiple conditions (e.g. hypertension, arrhythmia,
ischaemic cardiomyopathy, etc.).
Another limitation that could be envisioned relates to the
development of patient proﬁles by combining selected clinical
variables, which could lead to hypothetical cases that rarely occur
in daily practice. However, recommendations for these theoretical
cases might never appear.
Furthermore, the outcome of such kind of approach is less
subject to validation. The ultimate validation study would be a
patient outcome study, which is theoretically feasible but
practically very extensive, complex and time-consuming. Other
types of validation studies could include inter-panel comparisons
(national versus international, epileptologists versus general
neurologists, etc.).
5. Conclusions
The Epi-Scope1 tool is a unique and easy reference format to
view the panel’s treatment recommendations for adult patients
with epilepsy. Because of the validity of the RAM used and the
broad applicability of the study results in terms of patient
characteristics, the electronic decision tool supports practicing
neurologists in making appropriate treatment decisions for highly
speciﬁc patients with epilepsy.
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